Cargando…
Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection
BACKGROUND: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infection, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392558/ https://www.ncbi.nlm.nih.gov/pubmed/36054979 http://dx.doi.org/10.1016/j.thromres.2022.08.020 |
_version_ | 1784771089494179840 |
---|---|
author | Kovac, Mirjana Mitic, Gorana Milenkovic, Marija Basaric, Dusica Tomic, Branko Markovic, Olivera Zdravkovic, Marija Ignjatovic, Vera |
author_facet | Kovac, Mirjana Mitic, Gorana Milenkovic, Marija Basaric, Dusica Tomic, Branko Markovic, Olivera Zdravkovic, Marija Ignjatovic, Vera |
author_sort | Kovac, Mirjana |
collection | PubMed |
description | BACKGROUND: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infection, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia. METHODS: This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 patients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020–November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis. RESULTS: Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with thrombophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia. CONCLUSION: Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect. |
format | Online Article Text |
id | pubmed-9392558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93925582022-08-22 Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection Kovac, Mirjana Mitic, Gorana Milenkovic, Marija Basaric, Dusica Tomic, Branko Markovic, Olivera Zdravkovic, Marija Ignjatovic, Vera Thromb Res Full Length Article BACKGROUND: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infection, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia. METHODS: This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 patients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020–November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis. RESULTS: Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with thrombophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia. CONCLUSION: Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect. Elsevier Ltd. 2022-10 2022-08-20 /pmc/articles/PMC9392558/ /pubmed/36054979 http://dx.doi.org/10.1016/j.thromres.2022.08.020 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Full Length Article Kovac, Mirjana Mitic, Gorana Milenkovic, Marija Basaric, Dusica Tomic, Branko Markovic, Olivera Zdravkovic, Marija Ignjatovic, Vera Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection |
title | Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection |
title_full | Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection |
title_fullStr | Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection |
title_full_unstemmed | Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection |
title_short | Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection |
title_sort | thrombosis risk assessment in patients with congenital thrombophilia during covid - 19 infection |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392558/ https://www.ncbi.nlm.nih.gov/pubmed/36054979 http://dx.doi.org/10.1016/j.thromres.2022.08.020 |
work_keys_str_mv | AT kovacmirjana thrombosisriskassessmentinpatientswithcongenitalthrombophiliaduringcovid19infection AT miticgorana thrombosisriskassessmentinpatientswithcongenitalthrombophiliaduringcovid19infection AT milenkovicmarija thrombosisriskassessmentinpatientswithcongenitalthrombophiliaduringcovid19infection AT basaricdusica thrombosisriskassessmentinpatientswithcongenitalthrombophiliaduringcovid19infection AT tomicbranko thrombosisriskassessmentinpatientswithcongenitalthrombophiliaduringcovid19infection AT markovicolivera thrombosisriskassessmentinpatientswithcongenitalthrombophiliaduringcovid19infection AT zdravkovicmarija thrombosisriskassessmentinpatientswithcongenitalthrombophiliaduringcovid19infection AT ignjatovicvera thrombosisriskassessmentinpatientswithcongenitalthrombophiliaduringcovid19infection |